p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.

• DOI: 10.1200/jco.1996.14.5.1604
• Publication Date: 2017-02-24T09:48:15Z
• Authors: R Silvestrini; E Benini; S Veneroni; M G Daidone; G Tomasic; P Squicciarini; B Salvadori
• Keywords: Breast Neoplasms; Middle Aged; Prognosis; Combined Modality Therapy; Proto-Oncogene Mas; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; 0302 clinical medicine; Predictive Value of Tests; Outcome Assessment, Health Care; Proto-Oncogenes; Humans; Regression Analysis; Female; Genes, Tumor Suppressor; Aged; Follow-Up Studies

BACKGROUND AND PURPOSE The tumor-suppressor gene TP53 and the proto-oncogene bcl-2 encode, respectively, for a nuclear phosphoprotein mitochondrial protein involved in multiple cellular functions. proteins provide prognostic information node-negative breast cancer are supposed to influence treatment responsiveness. We analyzed predictive role of p53 expression, alone association with other variables, postmenopausal women node-positive, estrogen receptor-positive (ER+) cancers treated radical or conservative surgery plus radiotherapy adjuvant tamoxifen at least 1 year. PATIENTS METHODS On 240 resectable cancers, we determined expression bcl-2, using immunohistochemistry, cell proliferation (3H-thymidine labeling index [3H-dT LI]), ER progesterone receptors (PgR). RESULTS 3H-dT LI were weakly related one another both unrelated bcl-2. Relapse-free distant metastasis-free survival 5 years significantly lower patients tumors that highly expressed (P = .0001) those did not express .02). However, p53, but provided independent tumor size, axillary node involvement, steroid receptors, LI. Moreover, simultaneous overexpression lack PgR identified maximum risk relapse, whereas overexpression, associated low presence PgR, improved resolution low-risk patients. CONCLUSION appears be indicative clinical outcome tamoxifen. Whether weak indicators biologic aggressiveness, regardless treatment, hormone resistance remains defined.